Background. Immunosuppressants can induce hepatitis B virus (HBV) reactivation; however, informative data about the risk of different immunosuppressive regimens, including biologics, on HBV reactivation (HBVr) among patients with rheumatoid arthritis (RA) are incomplete.
Hepatitis B virus (HBV) infection is the major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC) [1] [2] [3] . There are already 248 million people worldwide chronically infected by HBV [4] . Hepatitis B virus reactivation (HBVr) is an emerging issue and a potentially life-threatening complication to patients whose immune system is deficient or suppressed. It is estimated that the risk of HBVr ranges 20%-50% in hepatitis B surface antigen (HBsAg)-positive patients undergoing chemotherapy or immunosuppressive therapy [5] . Not only HBsAgpositive patients but also HBsAg-negative/antibody to hepatitis B core antigen (anti-HBc)-positive patients (resolved hepatitis B) are at risk of HBVr [6, 7] . However, most of the data were derived from patients with cancers and undergoing chemotherapy.
Rheumatoid arthritis (RA) is the most common inflammatory arthritis derived from autoimmunity. This chronic, symmetrical polyarthritis predominantly affects females. Glucocorticoid (GC) plays a central role in the treatment of RA and has been proven to increase HBV viral replication by binding to the GC responsive element [8, 9] . Synthetic disease-modifying antirheumatic drugs (sDMARDs) are frequently combined depending on the disease activity to minimize long-term exposure to high-dose GC. A number of case reports have described that sDMARDs, especially methotrexate, have the potential to increase the risk of HBVr [10, 11] . Biological disease-modifying antirheumatic drugs (bDMARDs), medicinal products manufactured from a variety of natural sources, offer alternative options for effective treatment of RA. Recently, the American Gastroenterological Association (AGA) Institute proposed a ranking for the risk of HBVr among chemotherapeutic agents and immunosuppressants [12, 13] . According to the report, rituximab has the highest risk of HBVr in both HBsAg-positive patients and patients with resolved hepatitis B, whereas tumor necrosis factor α (TNF-α) inhibitors are classified as moderate-risk for HBVr in HBsAg-positive carriers, and prophylactic antiviral therapy is conditionally recommended. However, the rankings were based on few studies with limited case numbers among rheumatic patients. Besides, RA patients usually took >1 kind of immunosuppressant. The actual risk of HBVr by biologics in RA patients still deserves investigation. It remains unknown whether antiviral prophylaxis therapy is required when GC is combined with bDMARDs in use.
The aim of this study was to delineate the impact of bDMARDs, as well as mono or combination immunosuppressive regimens, on HBVr in HBsAg-positive cases through mass screening of RA patients.
METHODS

Patients
We retrospectively reviewed 2334 RA patients who had available HBsAg data in Taipei Veterans General Hospital between January 2006 and December 2012. One hundred twenty-three patients were positive for HBsAg at the time of diagnosis or before immunosuppressive treatment without receiving anti-HBV prophylaxis. The detailed medical records, including immunological profiles, clinical courses, and outcomes, were recorded. The diagnosis of RA was based on the 1987 American College of Rheumatology criteria [14] or 2010 American College of Rheumatology/European League Against Rheumatism collaborative initiative classification criteria [15] . This study was approved by the institutional review board of Taipei Veterans General Hospital according to ethical guidelines and carried out in accordance with standards of the Declaration of Helsinki.
Immunosuppressive Therapy in Rheumatoid Arthritis
The SDMARDs in this study included methotrexate, hydroxychloroquine, sulfasalazine, and so on. The bDMARDs included anti-TNF-α agents, rituximab (anti-CD20 monoclonal antibody), tocilizumab (anti-interleukin 6 receptor monoclonal antibody), and abatacept (cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin). A drug exposure was considered when a patient took GC, sDMARDs, or bDMARDs for >4 weeks.
Definition
Hepatitis B virus reactivation was defined as either an increase in HBV DNA >1 Log10 IU/mL compared with baseline or 3-fold increase in serum alanine aminotransferase (ALT) level accompanied with HBV DNA > 100 000 copies/mL (20 000 IU/ mL) in cases without baseline HBV load [16] . Other causes of liver damage, such as autoimmune hepatitis, hepatitis C virus, hepatitis D virus coinfection, and drug-induced liver injury, had been carefully reviewed according to chart records. All HBsAgpositive patients with autoimmune diseases had baseline ALT levels <1.5 times the upper limit of normal (ULN; 40 U/L) in this study. The definition of severe hepatitis was a hepatitis flare with an ALT increase to >10-fold the upper limit of normal [17] , and liver decompensation was defined as a serum total bilirubin level >2 mg/dL and/or prolongation of prothrombin time for >3 seconds [18] .
Serological Tests of Viral Hepatitis Markers
Serum ALT, aspartate aminotransferase (AST), and bilirubin were measured by a 24-factor automated chemical analyzer and standard reagents. Hepatitis B surface antigen was determined by radioimmunoassay or enzyme immunoassay. Hepatitis B virus load was quantified by the Roche Cobas Tagman HBV DNA assay (detection limit of 12 IU/mL).
Statistical Analysis
The duration of the patient's follow-up was calculated from the time of treatment for RA to the date of HBVr, the last visit, or death. The occurrence of HBVr was carefully reviewed since starting GC, sDMARD, or bDMARD treatments for all studied cases. To ascertain the true effect of bDMARDs on reactivation, the duration of treatment for those treated with bDMARDs was recalculated from the time of bDMARDs use. Chi-squared tests or Fisher's exact tests were used to compare the baseline characteristics among patients with or without HBVr. The cumulative risk of HBVr and overall survival were estimated using KaplanMeier methods, and the statistical differences were tested by log-rank tests. Cox's proportional hazards models were used to identify the associated risk factors for HBVr. The proportional hazards assumption was tested by Schoenfeld residuals before using the model. P values < .05 were considered statistically significant. All analyses were performed using the SAS statistical software package version 9.4.
RESULTS
Study Population
Among 123 patients positive for HBsAg without receiving anti-HBV prophylaxis, 98 (79.7%) were female, and the mean age at diagnosis was 49.5 years (Table 1) . Three (3.3%) patients were positive for hepatitis B e antigen (HBeAg). The mean baseline levels of ALT and AST were 22.4 and 23.5 U/L, respectively. The median baseline HBV load was 445 IU/mL (ranged from undetectable to 71 000 IU/mL) in 46 cases available for baseline HBV DNA data. Fifty-one RA patients received GC therapy; all patients (n = 123) had sDMARDs treatment. Biological disease-modifying antirheumatic drugs were administered in 36 patients: 26 received anti-TNF-α agents, 6 received rituximab, 2 received tocilizumab, and 2 received abatacept.
Incidence and Baseline Characteristics of Hepatitis
B Virus Reactivation
After the follow-up of 3459 person-months (mean = 28.1 months/patient), 30 patients developed HBVr, an incidence rate of 8.6 per 1000 person-months ( Table 1 ). The mean time to HBVr was 13.6 ± 11.5 months after the start of immunosuppressants, sDMARDs, or bDMARDs. Patients developing HBVr had higher baseline serum HBV load than those without HBVr among cases with available HBV DNA data (P = .03). The frequency of GC use was significantly higher in patients with HBVr versus those without HBVr (60.0% vs 35.5%; P = .02). However, the frequency of bDMARD use was similar between patients with and without HBVr (40.0% vs 25.8%; P = .14). According to the treatment regimens, patients were classified into 4 groups: sDMARDs alone (n = 50), sDMARDs in combination with bDMARDs (n = 22), GC in combination with sDMARDs (n = 37), and GC in combination with sDMARDs and bDMARDs (n = 14). The risk of HBVr was associated with the regimens of immunosuppressant (P = .002). There were no differences in age at diagnosis, sex, and baseline serum ALT/ AST levels between those with and without HBVr (all P < .05) ( Table 1) .
The median baseline HBV load was 132 IU/mL (ranged from undetectable to 34 400 IU/ml) in the sDMARDs alone group, 41 IU/mL (ranged from undetectable to 812 IU/ml) in the sDMARDs in combination with bDMARDs group, 2350 IU/ mL (ranged from 64 to 71 000 IU/ml) in the GC in combination with sDMARDs group, and 721 IU/mL (ranged from undetectable to 1830 IU/ml) in GC in combination with sDMARDs and bDMARDs group. The peak HBV loads during HBVr ranged 3800->170 000 000 IU/mL; the peak ALT levels ranged 105-2207 IU/mL; and the peak total bilirubin level ranged 0.43-23.31 mg/dL.
Factors Associated With Hepatitis B Virus Reactivation
In univariate analysis, older age, male sex, HBeAg status, and baseline ALT level were not associated with HBVr (P > .05) ( Table  2) . Glucocorticoid was associated with the risk of HBVr with the unadjusted hazard ratio (HR) of 2.29 (P = .03) ( Table 2 and Figure  1A ). Biological disease-modifying antirheumatic drugs were not significantly associated with HBVr (HR = 1.81; 95% CI = .87 to 3.77; P = .11). Glucocorticoid in combination with sDMARDs and bDMARDs had the highest risk of HBVr, compared with sDMARDs alone (HR = 4.83; 95% CI = 1.90-12.25; P = .0009) ( Table 2 and Figure 1B ). In the multivariate Cox proportional hazard model (Table 3) , GC was an independent risk factor for HBVr after adjustment for age, sex, HBeAg status, baseline ALT and AST level, and bDMARD use (adjusted HR = 2.68; 95% CI = 1.24 to 5.81; P = .01). When classified by the immunosuppressive regimens, GC in combination with sDMARDs and bDMARDs significantly increased the risk of HBVr after adjustment for other associated factors (HR = 5.14; 95% CI = 1.77-14.92; P = .003) ( Table 3) .
Varied Biological Disease-Modifying Antirheumatic Rrugs on the
Risk of Hepatitis B Virus Reactivation
Of the 36 HBsAg-positive patients undergoing biologics treatment, 26 were on anti-TNF-α agents, 6 were on rituximab, 2 were on abatacept, and 2 were on tocilizumab. All patients receiving bDMARDs received sDMARD treatment simultaneously. Of these, 12 (33.3%) cases developed HBVr (8 on anti-TNF-α agents, 3 on rituximab, 1 on abatacept treatment). Patients who developed HBVr had a higher proportion of GC cotreatment compared with those who did not experience HBVr (75.0% vs20.8%; P = .003) (Supplementary Table 1 ). Among patients who received bDMARD and sDMARD combination therapy, GC significantly increased the risk of HBVr (HR = 6.6; 95% CI = 1.77-24.53, P = .005) ( Table 4 and Figure 1C ). Glucocorticoid was an independent risk factor for HBVr after adjusting for other risk factors in the multivariate model (Table 5 ). When the class of bDMARDs was included in the model, the adjusted hazard ratio for GC was 26.37 (95% CI = 3.16-220.25; P = .003), and the hazard ratio for rituximab was 16.51 (95% CI = 1.82-149.67; P = .01).
Outcomes of Rheumatoid Arthritis Patients With Hepatitis
B Virus Reactivation
Antiviral therapy was promptly administered to the 30 patients at the time of HBVr. Of them, 22 (73.3%) received entecavir, 5 (16.7%) received lamivudine, 2 (6.7%) received telbivudine, and 1 (3.3%) received adefovir treatment. Thirteen (43.3%) patients developed severe hepatitis, whereas liver decompensation occurred in 5 (16.7%) patients despite deferred antiviral Table 2 and Figure 1D ). After adjusting for other factors, the multivariate analysis (Table 6) showed that HBVr had a trend to associate with mortality (adjusted HR = 8.33; P = .09).
DISCUSSION
In this study, we investigated the risk of HBVr under different immunosuppressant regimens in patients with RA, an area that had not been well studied before. Out findings suggested that GC is one of the major risk factors for HBVr in RA patients as well as in bDMARD-treated patients. In addition, immunosuppressive treatment with a combination of GC, sDMARDs, and bDMARDs has the highest risk of HBVr. Among the classes of bDMARDs, rituximab shows the leading risk of HBVr. Similar to cancer patients who were HBV carriers undergoing chemotherapy, RA patients receiving immunosuppressive therapy also have risk of HBVr [12] . Chemotherapy is often administered in the short-term period, whereas long-term immunosuppressive therapy is generally required for chronic autoimmune diseases such as RA. Even though immunosuppressive therapy is effective in maintaining disease remission, long-term use can impair host immune functions and increase the risk of infection. In previous studies, HBVr has been reported in autoimmune disease patients who received GC and sDMARDs [8] [9] [10] [11] . Recently, increasing evidence has suggested that bDMARDs are also related to HBVr [11, 16, 19, 20] . Tumor necrosis factor α is believed to be involved in HBV-specific cytotoxic T-cell response and provides protective effect against HBV [21] [22] [23] . Therefore, TNF-α inhibitor may allow HBV to evade host antiviral immune surveillance, thereby leading to subsequent HBVr [24] . Recent studies have suggested that the risk of HBVr associated with TNF-α inhibitor treatment widely ranged 12.3%-62.5% [16, 25, 26] . However, the reported case numbers were extremely small, and these analyses did not take the effect of combination regimens into consideration. Lee et al reviewed 9 studies that involved a total of 122 patients and 15 (12.3%) developed HBVr [19] . Another retrospective study revealed that HBVr developed in 5 (62.5%) of 8 RA patients who were positive for HBsAg after anti-TNF-α therapy [16] . It is worth noting that all 5 patients developed HBVr while receiving GC and sDMARD combination therapy. Our data showed that GC is a main risk factor of HBVr in RA patients undergoing sDMARD or bDMARD treatment. The mean dose of prednisolone in our patients was only 7.2 mg/day (range = 2.5-40 mg/day). The median doses of GC in GC in combination with To analyze the effect of GC on HBVr, <10 mg/ day was defined as a low dose, 10-20 mg/day was defined as a moderate dose, and >20 mg/day was defined as a high dose [13] . As shown in Supplementary  Table 3 , 35 patients received a low dose of GC, 15 received a moderate dose, and 1 received a high dose. The incidence of HBVr was higher in patients with higher GC dose (P = .01). One previous study suggested that multiple immunosuppressant treatment can increase the risk of HBVr [27] . In that study, use of >2 immunosuppressants (GC, sDMARDs, or anti-TNF-α) was an independent predictor of HBVr in HBsAg-positive patients with inflammatory bowel disease. Recently, the AGA Institute suggested antiviral prophylaxis for HBsAg-positive patients receiving either anti-TNF-α treatment or low-dose corticosteroids for >4 weeks with conditional recommendation, but steroid dosing alone or combined with other agents would justify prophylaxis [13] . Our data support this recommendation. We also noted that the rate of HBVr was lower in the sDMARDs in combination with bDMARDs group when compared with the sDMARDs alone group. Small number size may explain this finding, but we believe that the risk of HBV reactivation among the bDMARDs is different; for examples, anti-CD20 antibody therapy presents a higher risk than TNF-α blocker for HBVr. As shown in Supplementary  Table 4 , sDMARDs only, bDMARDs (except anti-CD20) in combination with sDMARDs, and sDMARDs in combination with low-dose GC had a relative low risk of HBVr (<20%), but additive or synergistic effects contributed by GC or bDMARDs were observed in the combination therapy groups.
Rituximab is well known for its harmful effect on HBVr in patients with lymphoma, and recently the US Food and Drug Administration raised a warning on this issue [7, 28] . Rituximab therapy was reported to be safe in patients with rheumatic disease for its longer interval of dosing [29] . However, the incidence of HBVr under rituximab treatment was 40% and 100% in our HBsAg-positive RA patients without or with GC treatment, respectively. Our findings support the requirement of antiviral prophylaxis in HBsAg-positive RA patients receiving rituximab treatment.
Tocilizumab and abatacept might influence the patient's immune response to HBV. In this study, the effect of combination GC and sDMARDs treatment on HBVr in patients receiving tocilizumab or abatacept was not well confirmed because of the small sample sizes, and further observation is needed.
Antiviral prophylaxis can prevent chemotherapy-induced HBVr in cancer patients who are positive for HBsAg and is recommended by American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), and Asian Pacific Association for the Study of the Liver (APASL) guidelines, but the recommendations were not justified according to the risk of HBVr in immunosuppressed patients [30] [31] [32] . The necessity of prophylactic antiviral therapy is controversial for patients at moderate risk of HBVr, as recommended by the AGA [20] . Our data suggest that the risk of HBVr increases under combination immunosuppressive therapy. The risk of low dose GC in combination with sDMARDs and bDMARDs (except anti-CD20) was around 54.5%, which was higher than the 5.9% risk of bDMARDs (except anti-CD20) in combination with sDMARDs or the 12.5% risk of sDMARDs in combination with low-dose GC (Supplementary Table 4 ). These results imply that combination therapy with not only GC but also bDMARDs can increase the risk of HBVr. Closely monitoring HBV DNA instead of antiviral prophylaxis can be recommended for RA patients undergoing sDMARD monotherapy or sDMARD therapy in combination with bDMARDs (except for B-cell-depleting agents). However, when a moderate dose of GC, or CD20 blocker, or bDMARDs with any dose of GC is applied, prophylactic antivirals should be provided soon to prevent catastrophic outcome.
There were a few limitations in this study. First, it was a retrospective design. Second, the sample size of HBV carriers in patients with RA was not big. However, we screened 2334 patients with RA, and the case number for HBsAg-positive patients is the largest so far among all reported studies apart from those with a meta-analysis design. Finally, the cumulated dosage of the immunosuppressive agents, a possible factor of HBVr, was not taken into consideration in this study.
In conclusion, HBVr is common in HBsAg-positive RA patients, especially under GC-combined immunosuppressive The covariates considered in the stepwise variable selection procedure with the significance level for entry (SLE) and the significance level for stay (SLS) set to 0.15 during the regression analysis were age, sex, alanine aminotransferase, aspartate aminotransferase, hepatitis B e antigen, tumor necrosis factor α blocker, rituximab, other biologics, and glucocorticoid.
Abbreviations: CD20, rituximab; HR, hazard ratio; Others, other biologics (abatacept and tocilizumab); TNF, tumor necrosis factor α blocker.
treatments. Antiviral prophylaxis should be justified according to the risk of HBVr in rheumatic patients receiving different immunosuppressive regimens.
Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author. The covariates considered in the stepwise variable selection procedure with the significance level for entry (SLE) and the significance level for stay (SLS) set to 0.15 during the regression analysis were age, sex, alanine aminotransferase, biological disease-modifying antirheumatic drugs, glucocorticoid, and hepatitis B virus reactivation.
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